Bangalore, India – Molecular Connections today announced the licensing of its NetPro™ Database to Lion Bioscience Research Inc. (LBRI).

NetPro™, Molecular Connections’ proprietary protein interaction database covers more than 30,000 expert curated and annotated protein-protein interactions. NetPro™ has been built using interaction data extracted with the company’s proprietary information extraction engine, M-CHIPS™. All the interactions are from peer reviewed published scientific literature and have been validated through manual cross-checking by Molecular Connections’ in-house scientific team. Molecular Connections will issue subsequent updates to the database, which will include the latest advances recorded in scientific literature.

The NetPro™ database is organized in standard relational database format with built in front-end to effectively navigate and analyse the data. NetPro™ data is linked to public Ids (like LocusLink), facilitating integration of interactions information into proprietary drug discovery databases. The protein-protein interactions in NetPro™ are complemented with annotations of the profiled proteins with scientific literature information on a variety of important subjects, including –

* Cellular Localization
* Biological Pathways
* Species
* Experimental Technique
* Diseases implicated
* Gene Ontology

Anthony Caruso, President, Lion bioscience Research, Inc, mentioned “Protein interaction data are extremely valuable, but mostly only exists in the literature and not in well structured databases. The hand curated NetPro™ database provides a comprehensive and accurate account of known protein interactions, which will save us considerable time and money in our discovery efforts.”

Protein interactions play significant roles in various aspects of the structural and functional organization of the cell, and their elucidation sheds light on the molecular mechanisms of biological processes. Having a database of protein interactions will allow researchers to identify drugs that target pathways related to a specific disease while avoiding pathways associated with unwanted side effects and toxicity. Key to advancing our knowledge of biochemical pathways and networks is the intelligent analysis and mining of available literature, which is a large untapped resource containing information about thousands of interactions.

“Protein-protein interactions are critical factors regulating the normal functions of cells and unraveling the interacting partners of a protein of interest is an invaluable way of understanding innate protein function” said Jignesh Bhate, Molecular Connections’ Founder and Director. “Moreover, the ability to analyze a large network of interacting proteins, combined with gene expression data, will play a critical role in identifying and validating potential drug targets”.

About LBRI

LION Bioscience Research Inc. was founded as a subsidiary of LION Bioscience to develop and apply information technology exclusively for the Bayer group.

About LION Bioscience

LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. LION’s performance software solutions developed by its scientific and IT experts enable researchers to simultaneously compile and analyze data across various phases of the R&D process. Research time and costs are reduced, as scientists are able to identify and focus on the most promising drug candidates earlier.

LION sets the standard for integration solutions with more than 280 corporate and academic customers globally including AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Eli Lilly, GlaxoSmithKline, IBM, Incyte, Johnson&Johnson, Merck Inc., Nestlé, Novartis, Schering AG and Sumitomo Pharmaceuticals. LION’s solutions include SRS for bioinformatics data access, iDEA pkEXPRESS™ with analysis and prediction tools for ADME/tox, LION Target Engine™ for target identification and optimization, LION Lead Engine™ for lead identification and optimization, LION DiscoveryCenter™ for biological and chemical data and application integration and LION SolutionCenter™ for Professional Services.

Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, estimates, targets, goals and descriptions of future events. Such statements are based on the current targets that LION has set itself and on LION’s current expectations, each of which is subject to risks and uncertainties. LION’s actual results may vary materially from those targeted, expected or projected because of factors such as exchange rate fluctuations, uncertainties relating to technologies, product and solution development, acceptance by the market of LION’s offerings, market or industry trends, success of LION’s business model and strategy, competition, cost or pricing of LION’s products and solutions, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. We refer you to LION’s Annual Report on Form 20-F, as filed with the Securities and Exchange Commission (SEC) on June 18, 2002, as well as LION’s future SEC filings, in which these and other risk factors are discussed. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise. LION bioscience®, Life Science Informatics™, LION DiscoveryCenter™, LION SolutionCenter™, LION Hosted Services™, LION Target Engine™, LION Lead Engine™, LSI™, bioSCOUT®, arraySCOUT™, arrayTAG™, arrayBASE™, genomeSCOUT™, pathSCOUT™, pSCOUT™ and iDEA™ are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.